Ocasio-Cortez confronts the CEO for a price of nearly $ 2,000 on an HIV drug that costs $ 8 in Australia

by



[ad_1]

representative Alexandria Ocasio-CortezAlexandria Ocasio-CortezTlaib Becomes the First Muslim Woman to Chair the Energy Night Chamber: Dems Presses the Head of the Interior to Adopt Climate Action | Lawmakers disagree over regulation of chemicals in water | Warren releases climate plan for military defense overnight: lawmakers at the brink of tensions with Iran | Questions arise after state withdraws Iraqi staff | Senators demand a briefing | House Sign Advances Pentagon Expenditure Bill 0B | Warren Proposes Climate Threat Plan for Military PLUS (D-N.Y.) Thursday confronted a CEO on the pricing of a drug designed to reduce the risk of HIV transmission to $ 8 in Australia but more than $ 1500 in the United States.

"You're the CEO of Gilead, is it true that Gilead earned $ 3 billion in profits from Truvada in 2018?" Ocasio-Cortez asked Daniel O 'Day, CEO of Gilead.

"$ 3 billion in revenue," he said.

"The current price is $ 2,000 a month in the United States, is not it?" she asked, referring to Truvada.

"It's $ 1,780 in the United States," replied O. Day.

"Why is it $ 8 in Australia?" Ocasio-Cortez countered.

"Truvada is still protected by a patent in the United States and in the rest of the world, it is generic," said O. Day, adding that "the product will be generically available in the United States from September 2020" .

"I think it's important here that we notice that the public, we, the people, have developed this medicine.We have paid for this drug, we have developed and developed all the patents necessary for the creation of Prep: The patent belongs to the public who refused to apply it, "Ocasio-Cortez said.

"There's no reason it's $ 2,000 a month. People are dying because of this and there is no enforceable reason for that. "

Truvada is a prophylactic treatment against HIV or AIDS that reduces the risk of infection.

[ad_2]

Source link